Christopher Decotiis, MD
Pulmonary Disease · Summit, NJNPI 1346401130
Payments from drug & device makers
Across 155 payments — averaging $44.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- GSK$1K
- Pulmonx Corporation$251
- AstraZeneca$158
- Regeneron Healthcare Solutions, Inc.$128
- Sanofi$124
- plus $536 from 15 others
What the payments were for
- Travel & lodging$5919%
- Food & beverage$2,28133%
- Education$4,00058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $4,639 |
| GSK | 84 | $1,035 |
| Pulmonx Corporation | 4 | $251 |
| AstraZeneca | 10 | $158 |
| Regeneron Healthcare Solutions, Inc. | 9 | $128 |
| Sanofi | 7 | $124 |
| Mylan Specialty L.p. | 7 | $111 |
| Boehringer Ingelheim | 6 | $87 |
| Verona Pharma, Inc. | 3 | $54 |
| Insmed, Inc. | 3 | $39 |
| Amgen | 2 | $33 |
| Genentech USA, Inc. | 2 | $29 |
| Optinose US, Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Bio Products Laboratory USA, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $17 |
| Merck | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Octapharma USA, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,872 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 41 | $548,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 277 | $225,287 |
| XolairOmalizumab | 24 | $79,026 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $69,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $68,087 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $55,069 |
| Pirfenidone | 17 | $50,647 |
| Spiriva RespimatTiotropium Bromide | 29 | $25,631 |
| Spiriva HandihalerTiotropium Bromide | 20 | $19,016 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $13,410 |
| Arnuity ElliptaFluticasone Furoate | 22 | $8,720 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $8,676 |
| EliquisApixaban | 11 | $8,219 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 68 | $7,841 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $7,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $87 | $587,60495 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,035 | $358,755535 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $158 | $78,989143 claims |
| MerckDulera | $16 | $7,57119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Summit
- Robert SussmanSummit$645K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.